Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

Journal of the National Cancer Institute

Volumn 93, Issue 4, 2001, Pages 284-292

  Harro, Clayton D ^a   Pang, Yuk Ying Susana ^c   Roden, Richard B S ^b   Hildesheim, Allan ^d   Wang, Zhaohui ^e   Reynolds, Mary Jane ^a   Mast, T Christopher ^a   Robinson, Robin ^f   Murphy, Brian R ^g   Karron, Ruth A ^a   Dillner, Joakim ^e   Schiller, John T ^c   Lowy, Douglas R ^c,h  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Clinical Sciences   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f NOVAVAX INC   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; IMMUNOGLOBULIN G; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; PLACEBO; STRUCTURAL PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DILUTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION PAIN; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEROCONVERSION; SKIN MANIFESTATION; STATISTICAL ANALYSIS; SYMPTOM; VIRION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS TYPING; VOLUNTEER; WART VIRUS;

EID: 0035925074     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.4.284     Document Type: Article

References (41)

1. Estimates of worldwide incidence from 25 major cancers in 1990
2. Estimates of the worldwide mortality from 25 cancers in 1990
3. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop
4. Papillomaviruses
5. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
6. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
7. Papillomavirus-like particles and HPV vaccine development
8. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
9. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
10. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
11. Growing human papillomaviruses and virus-like particles in the laboratory
12. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles
13. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
14. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomaviruses
15. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
16. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
17. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli
18. Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells
19. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor
20. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
21. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope
22. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
23. Evaluation of seroreactivity to HPV16 virus-like particle in an incident case-control study of cervical neoplasia
24. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids
25. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
26. Practical statistics for medical research
27. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
28. HPV6b virus like particles are potent immunogens without adjuvant in man
29. Clinical evaluation in healthy adults of a hepatitis B vaccine made of recombinant DNA
30. Multicentre dose range study of a yeast-derived hepatitis B vaccine
31. A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity
32. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant
33. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast
34. Adjuvant properties of aluminum and calcium compounds
35. Selective IgG subclass expression: Biologic, clinical and functional aspects
36. The influence of virus structure on antibody responses and virus serotype formation
37. Correlation of antibodies in skin and serum with disease severity in pemphigus
38. Mucosal immunity to human papillomavirus in the female reproductive tract